恶性实体瘤放化疗后继发血液肿瘤患者临床及预后分析  

Hematological Neoplasms Secondary to Malignant Solid Tumors with Radiotherapy and Chemotherapy:a Clinical and Prognostic Analysis

作　　者：任娟[1,2] 卢林娜[2] 王刚 张睿娟[3] 马艳萍 杨林花[2] REN Juan;LU Lin-Na;WANG Gang;ZHANG Rui-Juan;MA Yan-Ping;YANG Lin-Hua(Shanxi Medical University,The Second Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;Department of Hematology,The Second Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;Department of Hematology,Shanxi Bethune Hospital,Taiyuan 030032,Shanxi Province,China)

机构地区：[1]山西医科大学,山西太原030001 [2]山西医科大学第二医院血液科,山西太原030001 [3]山西白求恩医院血液科,山西太原030032

出　　处：《中国实验血液学杂志》2023年第2期383-388,共6页Journal of Experimental Hematology

基　　金：山西省重点研发计划(201803D31123);山西白求恩医院人才引进科研项目(2021RC017)。

摘　　要：目的:探讨恶性实体瘤治疗相关血液肿瘤患者的临床特点、治疗及预后。方法:对山西医科大学第二医院收治的恶性实体瘤放化疗后继发血液肿瘤36例患者的临床特征、治疗及预后进行回顾性分析。结果:36例治疗相关血液肿瘤患者中位年龄60(47-81)岁,男性14例,女性22例;急性髓系白血病22例,急性淋巴细胞白血病5例,多发性骨髓瘤4例,骨髓增生异常综合征3例,非霍奇金淋巴瘤2例。恶性实体瘤至血液肿瘤发生的中位潜伏期为42.5(12-120)个月。治疗相关血液肿瘤中位生存时间为10.5(1-83)个月,3年总生存(OS)率为24.3%,治疗相关急性髓系白血病中位生存时间为7(1-83)个月,3年OS率为21.4%。结论:恶性实体瘤患者放化疗后其远期并发症治疗相关血液肿瘤预后差,需根据患者临床情况实施个体化治疗。Objective:To explore the clinical characteristics,treatment and prognosis of therapy-related hematological neoplasms patients secondary to malignant solid tumors.Methods:The clinical features,treatment and prognosis of 36 hematological neoplasms patients secondary to malignant solid tumors with radiotherapy and chemotherapy in the Second Hospital of Shanxi Medical University were retrospectively analyzed.Results:The 36 patients with therapy-related hematological neoplasms had a median age of 60(47-81)years,14 were male and 22 were female.Among them,22 cases were acute myeloid leukemia,5 cases were acute lymphoblastic leukemia,4 cases were multiple myeloma,3 cases were myelodysplastic syndrome,and 2 cases were non-hodgkin's lymphoma.The median latency of malignant tumor to hematological neoplasm was 42.5(12-120)months.The median survival time of therapy-related hematological neoplasms was 10.5(1-83)months,and the 3-year overall survival(OS)rate was 24.3%.The therapy-related acute myeloid leukemia patients had a very poor prognosis,with a median survival of 7(1-83)months and a 3-year OS rate of 21.4%.Conclusion:The prognosis of therapy-related hematological neoplasms secondary to malignant solid tumors with radiotherapy and chemotherapy is poor,and individualized treatment should be implemented according to the clinical situation of patients.

关 键 词：恶性肿瘤 血液肿瘤 化疗 放疗 

分 类 号：R733[医药卫生—肿瘤]